Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
V.ARCH
Alternate Symbol(s):
ACHFF
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok...
). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(290)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Apr 30, 2024 10:09pm
Insane Shorting
Todays wild swing from $1.90 to $1.56 on absolutely zero justifiable news is concerning. Its time the market enforcement division step in and investigate!!! This market manipulation needs to
...more
(290)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Apr 26, 2024 9:49am
Algorithms back in control
We had a nice run over the last 6 months with the share price going from $1 to $2.56. We had lits of material news released during this time frame. We dosed our first patient for the AKI phase 2 trial
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 16, 2024 7:14am
New Press Release - St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the...
read article.
(290)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Apr 03, 2024 9:10am
More Great News
Arch is on a roll snd just keeps pumping out more great news. We get another Canadian site, and it just happens to be the #1 Heart Hospital in Canada and top 10 in the world. We now have 8 sites on
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 03, 2024 7:00am
New Press Release - UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an academic research organization in the Department of Anesthesia and Pain Management at the University...
read article.
(290)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Apr 02, 2024 7:43am
3 more sites
Good newd continues to flow in here. 3 more sites in Turkey now dosing. My best guess the original 3 sites have already dosed about 15 people. I would suggest that the new sites would not have been
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 02, 2024 7:26am
New Press Release - Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...
read article.
(290)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Mar 27, 2024 3:34pm
RJ Analyst
Nothing but total silence from our sole analyst at Raymond James. This analyst has not commented on number of material news releases: 1. Increased dosage study 2. FDA Approval for New Phase 2
...more
(290)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Mar 27, 2024 11:04am
Algorithms
appear still be manipulating this stock. We had a very brief uptick in buying which lifted us to a new 52 week high which was nice to see but our single biggest challenge is we are 100% retail play
...more
(290)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Mar 18, 2024 8:38am
More Great News
Well we finally got the long overdue 3rd party peer review. Now we wait to see how Raymond James Analyst reacts, I betting he will give us a nice bump up plus we have our new repurposed drug trial
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Mar 18, 2024 8:14am
Arch BioPartners - LSALT Peptide Development
Arch believes that LSALT peptide has the potential to deliver a major breakthrough in the treatment of diseases where inflammation plays a major role. In August 2019, a scientific team led by
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Mar 18, 2024 7:42am
LSALT PEPTIDE - BRITISH MEDICAL JOURNAL PUBLICATION
Multicentre, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 18, 2024 7:28am
New Press Release - Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV-2 virus Phase II findings previously disclosed support dipeptidase-1 (DPEP...
read article.
(290)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Mar 15, 2024 4:37pm
More great News today
with 1 Canadian site in Calgary and two more coming plus additional 3 sites in Turkey which will bring us to 9. It will be a big bonus if we get a few USA sites get us to 12-15 total sites. Momentum
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 15, 2024 7:05am
New Press Release - University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
TORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of Calgary’s Cumming School of Medicine has joined the Phase II trial for LSALT peptide targeting the...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test
NOI Filed for Drill Program at Lithium/Uranium Project in Nevada
Silvercorp to Acquire Adventus for Implied Consideration of C$0.50 per Share
Meet one of the Strongest Contenders to Lead Canada’s Cannabis Market
Multiple High-Grade Gold Hits at the Tonopah Gold Project Including 90 Meters at 2.0 gpt Gold